A renal biopsy is required for the detection of glomerular IgA immune deposits, the diagnostic hallmark of IgA nephropathy (IgAN). The biopsy also provides critical information about the severity of the histopathologic changes utilized in the prognosis and selection of patients for treatment. 1 In reviewing the IgAN treatment dilemma, Appel and Waldman 2 attributed the absence of a single clear treatment approach applicable to all IgAN patients to two major reasons. First, the pathogenesis of IgAN remains unknown. There is no direct relationship between the glomerular IgA immune deposits' intensity and the extent of glomerular injury. This hinders the development of a specific therapy targeting the primary cause of the disease. Second, the course of IgAN presentation and progression is highly variable.
In regard to progression, an inordinate number of abnormalities have been described in association with IgAN as predictive markers. In an insightful review and critical analysis of 30 published studies on the role of clinical and histologic prognostic factors in IgAN, D' Amico 3 highlighted elevated serum creatinine level, severe proteinuria at presentation, and a high score of glomerular and tubulointerstitial lesions as strong predictors. However, he cautioned that these prognostic markers may fail to correctly predict outcome in the single patient, probably because of the heterogeneity of the disease. He concluded that IgAN is a spectrum of diseases sharing a common pathogenetic marker, the mesangial IgA immune deposits, with unknown mechanisms propagating damage in a discontinuous pattern. This conclusion is concordant with earlier and comprehensive experimental observations that emphasized the variable characteristics of the immune complexes, in particular the nature of the antigens and the molecular form of IgA, as the major determinants of glomerular injury. 4 Accordingly, the multivariable pathophysiologic processes that mediate initiation and progression of IgAN pose a challenge to predicting who is likely to develop renal failure to warrant an early and intensive treatment to slow down the rate of progression. The clinical findings of van Es et al. 5 (this issue) now meet this challenge.
To enhance the precision of the morphologic prognosis, several studies of IgAN used the technique of immunophenotyping to characterize and semiquantify the cellular infiltrate in the renal tissue. Because of restricted biopsy policy, most of these studies were biased toward selecting patients with impaired renal function and a high risk of progression. The real need is for prognostic markers that can be detected in renal biopsies of patients in the early stage of IgAN with a normal glomerular filtration rate (GFR) to identify those who will progress to renal failure. Recognizing this need, van Es et al. 5 conducted retrospective and comprehensive analysis that related the clinical course, over an 18-year period, to the morphologic and immunohistologic changes in renal biopsies from 50 IgAN patients grouped into either normal GFR (n = 31) or decreased GFR (n = 19) at biopsy. They used a panel of monoclonal antibodies against a variety of leukocytic markers -CD3, CD4, CD8, CD20, CD45, CD68, HLA-DR, and GMP-17 (see note regarding terminology below) -to immunophenotype and localize the renal infiltrates. In comparing the immunophenotype scores of 13 progressors and 18 non-progressors in the normal GFR group, they discovered that all the leukocytic markers, with the exception of CD68 (macrophages), were significantly higher in the progressors. This finding is consistent with previous reports. In the progressors who presented with normal GFR, statistical analysis of the morphologic changes and immunophenotypic parameters revealed NKG7 + (GMP-17 + )/CD8 + intraepithelial lymphocytes (IELs) in the tubules as the most sensitive marker with the highest likelihood ratio. Interstitial CD20 + (B cell) was equally sensitive with the second highest likelihood ratio. Univariate analysis of the clinical, histopathologic, and immunohistochemical parameters showed tubular atrophy, interstitial infiltrate, interstitial NKG7 + (GMP-17 + )/CD8 + T cells, interstitial CD20 + cells, and NKG7 + (GMP-17 + )/ CD8 + IELs as significant predictors. Further evaluation by multivariate analysis confirmed only the last two markers as predictors of progression in IgAN patients with normal GFR.
First a brief note to clarify the relationship between the term GMP-17 and the gene NKG7. Medley et al. 6 reported on the monoclonal antibody 2G9, used in this co m m e nt a r y study, and showed that it binds to a small protein in the cytoplasmic granules of natural killer cell lines, designated GMP-17 (for granule membrane protein of 17 kilodaltons). Searches of National Center for Biotechnology Information databases and the European Ensembl database reveal that there is no gene with the GMP-17 designation. Sequence analysis and homology search of the GMP-17 protein 6 revealed that it is a product of an already known gene, NKG7 (natural killer cell group 7 sequence). Thus, we use the gene name NKG7 in lieu of the term GMP-17. NKG7, a four-pass transmembrane protein, is a calcium ion channel that is highly expressed in natural killer cells and activated T-cell receptor-αβ-expressing CD8 + T cells (http://www.genecards.org/).
Despite the limited number of patients in the study by van Es et al., 5 highly significant predictive values were obtained for the interstitial CD20 + cells and the tubular NKG7 + /CD8 + IELs. As the authors acknowledge, an independent prospective study of a larger patient population is needed to confirm the clinical utility of these two markers. An alternative and expedient approach is to analyze the data by using the novel statistical method of least-angle regression, recently described by Lemley et al., 7 for investigating a large set of quantitative predictors of progression in a small number of IgAN patients. Concurrence of least-angle regression with the multivariate analysis will also reinforce the predictive value of these two markers. Regardless of the outcome, the results of van Es et al. 5 provide important insights into the immunologic mechanisms that may help in the development of new treatment focused on postglomerular injury.
Identification of interstitial CD20 + cells as a predictive marker of progression by van Es et al. 5 is concordant with the early findings by Sabadani et al. 8 Recently, Segerer and Schlöndorff 9 summarized their similar findings of interstitial CD20 + cells in IgAN, membranous nephropathy, and renal allografts. They also reviewed how B cells contribute to interstitial inflammation, whereby the chemokine receptor CXCR5 on B cells and its cognate ligand CXCL13/BLC in renal tissue play a major role in directing B cells' participation in renal interstitial inflammation and the formation of tertiary lymphoid organs. Renal tertiary lymphoid organs have Duffy antigen receptor for chemokines-positive vessels that serve as a conduit for leukocytic emigration from the circulation into the tubulointerstitium. The relationship among B cells, CD8 + cells, tertiary lymphoid organs, and development of tubulitis needs to be investigated.
Despite a vast amount of histopathologic evidence demonstrating that the presence of tubular atrophy is an indicator of poor outcome of renal function, the primary role of tubular injury has not been explored adequately in IgAN. The novel findings of van Es et al. 5 showing that NKG7 + /CD8 + IEL localization in the tubules is associated with progression also shed new light on Stress co mmentar y immune mechanisms mediating tubular injury. Tubulitis, invasion of the tubular epithelium by infiltrating T cells and macrophages, is a diagnostic feature of acute cellular rejection of renal allografts. 10 This raises the question of whether tubulitis in IgAN progressors recapitulates the same process. The answer is negative. As van Es et al. 5 document, there is a paucity of macrophages and CD4 + T lymphocytes infiltrating tubules of early IgAN progressors. In contrast, the tubulitis pattern of renal allografts is full of macrophages and mostly of CD4 + and CD8 + T cells that contain cytotoxic granules (perforin and granzyme A/B) or the cytotoxic effector ligand FasL. 10 The absence of both perforin and granzyme A/B from NKG7 + / CD8 + IELs in IgAN progressors is another important feature that contrasts with the allograft-infiltrating CD8 + cytotoxic T lymphocytes. Consequently, what are the immune mechanisms engaged by NKG7 + / CD8 + IELs that inflict tubular injury? The answer is unknown. However, on the basis of the localization of NKG7 + /CD8 + IELs in intact and atrophic tubules, we postulate two complementary mechanisms of adaptive and innate CD8 + T cell-mediated tubular injury. The first mechanism (schematized in Figure 1a ) proposes that the T-cell receptors on NKG7 + /CD8 + cells mediate the cytotoxic response to either cross-presented exogenous antigen or an endogenous antigen produced by the tubules. Also, the antiapoptotic action of transforming growth factor-β and interleukin-15, along with the expression of CD103 that binds to E-cadherin on tubular cells, allows NKG7 + /CD8 + IELs to persist and cause disruption of the tubular structure and function. The second mechanism (schematized in Figure 1b) proposes the innate immune response of the NKG7 + / CD8 + IELs as a mediator of tubulitis. The primary function of sentinel CD8 + IELs is to sustain epithelial integrity by eliminating stressed cells. The CD8 + IELs express a variety of NK cell-lineage receptors, among which is the NKG2D activating receptor. Under stress conditions, epithelial cells express major histocompatibility complex class I chain-related proteins (MICA or MICB) that serve as ligands of NKG2D, hence targeting the cells for cytolysis and elimination. These are minimal models inspired by the study of van Es et al. 5 Their clinical relevance needs to be ascertained in future investigations.
The seminal report by van Es et al. 5 will enhance the clinical utility of renal biopsy early in IgAN to predict progression. Importantly, the novel discovery of NKG7 + /CD8 + IELs' association with tubulitis implicates this specialized T-cell subset as a mediator of nephron injury. Finally, we envisage that targeted inhibition of NKG7 + /CD8 + cells could be of therapeutic value, especially as an adjunct supplement to other therapeutic strategies aimed at IgAN.
